Targeting BRCA2 deficiency with GSK3 inhibitors

Targeting BRCA2 deficiency with GSK3 inhibitors

<p>BRCA1 and BRCA2 tumour suppressors are essential for homologous recombination-mediated double-strand break repair and replication fork protection. Therefore, BRCA1 and BRCA2 are essential for cell viability. Deactivating mutations in one of these genes lead to genome instability and are ass...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριος συγγραφέας:	Zonderland, G
Άλλοι συγγραφείς:	Tarsounas, M
Μορφή:	Thesis
Έκδοση:	2017

Παρόμοια τεκμήρια

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
ανά: Tacconi, E, κ.ά.
Έκδοση: (2019)

Chlorambucil targets BRCA1/2‐deficient tumours and counteracts PARP inhibitor resistance
ανά: Eliana MC Tacconi, κ.ά.
Έκδοση: (2019-05-01)

Targeting BRCA1 and BRCA2 deficiencies with G-quadruplex-interacting compounds
ανά: Zimmer, J, κ.ά.
Έκδοση: (2016)

Targeting the BRCA1/2 deficient cancer with PARP inhibitors: Clinical outcomes and mechanistic insights
ανά: Ashwin Ragupathi, κ.ά.
Έκδοση: (2023-03-01)

Novel approaches for targeting BRCA2-deficient tumour cells
ανά: Tacconi, E
Έκδοση: (2015)

Sirtuin inhibition is synthetic lethal with BRCA1 or BRCA2 deficiency
ανά: Ilirjana Bajrami, κ.ά.
Έκδοση: (2021-11-01)

GSK-3 inhibitors induce chromosome instability
ανά: Staples Oliver D, κ.ά.
Έκδοση: (2007-08-01)

A transcription-based mechanism for oncogenic β-catenin-induced lethality in BRCA1/2-deficient cells
ανά: Rebecca A. Dagg, κ.ά.
Έκδοση: (2021-08-01)

Lithium and Therapeutic Targeting of GSK-3
ανά: Melinda E. Snitow, κ.ά.
Έκδοση: (2021-01-01)

The Role of GSK-3 in Cancer Immunotherapy: GSK-3 Inhibitors as a New Frontier in Cancer Treatment
ανά: Giuseppa Augello, κ.ά.
Έκδοση: (2020-06-01)

Targeting GPX4-mediated ferroptosis protection sensitizes BRCA1-deficient cancer cells to PARP inhibitors
ανά: Xuexia Xie, κ.ά.
Έκδοση: (2024-10-01)

Machine Learning for Discovery of GSK3β Inhibitors
ανά: Patricia A. Vignaux, κ.ά.
Έκδοση: (2020-10-01)

GSK-3 inhibitors: preclinical and clinical focus on CNS
ανά: Hagit eEldar-Finkelman, κ.ά.
Έκδοση: (2011-10-01)

GSK-3 Inhibitors and Tooth Repair: An Ethical Analysis
ανά: Sorin Hostiuc, κ.ά.
Έκδοση: (2019-01-01)

Sustained delivery of PARP inhibitor Talazoparib for the treatment of BRCA-deficient ovarian cancer
ανά: Shicheng Yang, κ.ά.
Έκδοση: (2023-05-01)

A Novel PARP Inhibitor YHP-836 For the Treatment of BRCA-Deficiency Cancers
ανά: Tingting Du, κ.ά.
Έκδοση: (2022-07-01)

PARP inhibitors: review of mechanisms of action and BRCA1/2 mutation targeting
ανά: Karolina N. Dziadkowiec, κ.ά.
Έκδοση: (2017-02-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity.
ανά: Tacconi, E, κ.ά.
Έκδοση: (2017)

Identification of a RAD52 Inhibitor Inducing Synthetic Lethality in BRCA2-Deficient Cancer Cells
ανά: Qianye Yang, κ.ά.
Έκδοση: (2021-04-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
ανά: Zatreanu, D, κ.ά.
Έκδοση: (2021)

Targeting of CRMP-2 to the primary cilium is modulated by GSK-3β.
ανά: Young Ou, κ.ά.
Έκδοση: (2012-01-01)

BRCA1 and BRCA2 tumor suppressors protect against endogenous acetaldehyde toxicity
ανά: Eliana MC Tacconi, κ.ά.
Έκδοση: (2017-07-01)

Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
ανά: Julieta Martino, κ.ά.
Έκδοση: (2023-04-01)

The GSK3 kinase inhibitor lithium produces unexpected hyperphosphorylation of β-catenin, a GSK3 substrate, in human glioblastoma cells
ανά: Ata ur Rahman Mohammed Abdul, κ.ά.
Έκδοση: (2018-01-01)

Polθ inhibitors elicit BRCA-gene synthetic lethality and target PARP inhibitor resistance
ανά: Diana Zatreanu, κ.ά.
Έκδοση: (2021-06-01)

The inhibitors of cyclin-dependent kinases and GSK-3β enhance osteoclastogenesis
ανά: Yosuke Akiba, κ.ά.
Έκδοση: (2016-03-01)

Novel reporter alleles of GSK-3α and GSK-3β.
ανά: William B Barrell, κ.ά.
Έκδοση: (2012-01-01)

Correction: Inhibitors of Rho kinases (ROCK) induce multiple mitotic defects and synthetic lethality in BRCA2-deficient cells
ανά: Julieta Martino, κ.ά.
Έκδοση: (2023-11-01)

Targeting GSK3 and Associated Signaling Pathways Involved in Cancer
ανά: Przemysław Duda, κ.ά.
Έκδοση: (2020-04-01)

BRCA1 and BRCA2 deficient tumour models generate distinct ovarian tumour microenvironments and differential responses to therapy
ανά: Salar Farokhi Boroujeni, κ.ά.
Έκδοση: (2023-11-01)

GSK-3α Is a Novel Target of CREB and CREB-GSK-3α Signaling Participates in Cell Viability in Lung Cancer.
ανά: Sin-Aye Park, κ.ά.
Έκδοση: (2016-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232
ανά: Robert A. Smith, κ.ά.
Έκδοση: (2023-01-01)

Intrinsic resistance of HIV-2 and SIV to the maturation inhibitor GSK2838232.
ανά: Robert A Smith, κ.ά.
Έκδοση: (2023-01-01)

Glycogen synthase kinase 3 (GSK-3) and its inhibitors : drug discovery and development /
ανά: Martinez, Ana, 1961-, κ.ά.
Έκδοση: (2006)

Synthetic viability by BRCA2 and PARP1/ARTD1 deficiencies
ανά: Xia Ding, κ.ά.
Έκδοση: (2016-08-01)

1111 Targeting lipid metabolism to improve PARP inhibitor response in BRCA-associated TNBC
ανά: Geoffrey I Shapiro, κ.ά.
Έκδοση: (2023-11-01)

BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2.
ανά: Melissa S Cline, κ.ά.
Έκδοση: (2018-12-01)

Role of GSK-3β Inhibitors: New Promises and Opportunities for Alzheimer’s Disease
ανά: Suggala Ramya Shri, κ.ά.
Έκδοση: (2023-11-01)

Discovery of Novel Imidazopyridine GSK-3β Inhibitors Supported by Computational Approaches
ανά: Rosa Buonfiglio, κ.ά.
Έκδοση: (2020-05-01)

Computational study of some cancer drugs as potent inhibitors of GSK3β
ανά: David Ebuka Arthur, κ.ά.
Έκδοση: (2020-11-01)